Then an in-house MS2 database (BiotreeDB) was applied in metabolite annotation. The cutoff for annotation was set at 0.3.
"],"repository":["MetaboLights"],"study_status":["Public"],"ptm_modification":[""],"instrument_platform":["Liquid Chromatography MS -"],"chromatography_protocol":["LC-MS/MS analyses were performed using an UHPLC system (UltiMate 3000 UHPLC Systems, Thermo Fisher Scientific) with a UPLC BEH Amide column (2.1 mm x 100 mm, 1.7 μm) coupled to Orbitrap Exploris 120 mass spectrometer (Orbitrap MS, Thermo). The mobile phase consisted of 25 mmol/L ammonium acetate and 25 ammonia hydroxide in water (pH = 9.75) (A) and acetonitrile (B). The auto-sampler temperature was 4 °C, and the injection volume was 2 μL.
"],"publication":["RBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death."],"submitter_name":["Jiayi Ma"],"submitter_affiliation":["Shanghai JiaoTong University"],"organism_part":["Serum"],"technology_type":["mass spectrometry"],"disease":[""],"extraction_protocol":["Eighty μL of sample was transferred to an EP tube. After the addition of 320 μL of extract solution (methanol: acetonitrile= 1: 1, containing isotopically-labelled internal standard mixture), the samples were vortexed for 30 s, sonicated for 10 min in ice-water bath, and incubated for 1 h at -40 ℃ to precipitate proteins. Then the sample was centrifuged at 12000 rpm(RCF=13800(×g),R= 8.6cm) for 15 min at 4 °C. The resulting supernatant was transferred to a fresh glass vial for analysis. The quality control (QC) sample was prepared by mixing an equal aliquot of the supernatants from all of the samples.
"],"organism":["Homo sapiens"],"data_transformation_protocol":["The raw data were converted to the mzXML format using ProteoWizard and processed with an in-house program, which was developed using R and based on XCMS, for peak detection, extraction, alignment and integration.
"],"study_factor":["Disease","RBC-IMM score"],"submitter_email":["longestma@163.com"],"metabolights_link":["https://www.ebi.ac.uk/metabolights/MTBLS10792"],"sample_collection_protocol":["Before the treatment of CDK4/6 inhibitor, two milliliters of peripheral venous blood of the patients were drawn. After 1-2 h standing, the samples were centrifuged at 1500 rpm, 4 °C for 15 min, and then the supernatant was dispensed into a new tube. If testing is not conducted temporarily, keep the sample in a -80 degree fridge.
"],"omics_type":["Metabolomics"],"study_design":["CDK4/6 Inhibition","untargeted metabolites","cancer"],"curator_keywords":["CDK4/6 Inhibition","untargeted metabolites","cancer"],"mass_spectrometry_protocol":["The Orbitrap Exploris 120 mass spectrometer was used for its ability to acquire MS/MS spectra on information-dependent acquisition (IDA) mode in the control of the acquisition software (Xcalibur, Thermo). In this mode, the acquisition software continuously evaluates the full scan MS spectrum. The ESI source conditions were set as following: sheath gas flow rate as 50 Arb, Aux gas flow rate as 15 Arb, capillary temperature 320 °C, full MS resolution as 60000, MS/MS resolution as 15000 collision energy as 10/30/60 in NCE mode, spray Voltage as 3.8 kV (positive) or -3.4 kV (negative), respectively.
"],"metabolite_name":["L-Phenylalanine","Halosulfuron-methyl","Indoxyl sulfate","2-Hydroxy-3-methylbutyric acid","Galactinol","1,2,3-Trihydroxybenzene","Threonic acid","3-Methoxy-4-hydroxyphenylethyleneglycol sulfate","Parabanic Acid","D-Alanine","4-Hydroxy-3-methylbenzoic acid","Ethylmalonic acid","D-GalA","1-Deoxy-D-xylulose 5-phosphate"],"additional_accession":[]},"is_claimable":false,"name":"RBC Balanced Immuno-inflammatory Signatures Identify Advanced Breast Cancer Patients on CDK4/6 Inhibitors at Increased Risk of Progression and Death","description":"Recent studies show red blood cell (RBC) plays an essential role in regulating immunity. Nevertheless, the association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) patients receiving cyclin-dependent kinases 4/6 inhibitor (CDKI). Herein, the predictive and prognostic performance of novel RBC balanced immuno-inflammatory (RBC-IMM) parameters is evaluated relative to classical-IMM ones. A total of 100 CDKI-treated ABC patients are included. The RBC-IMM score prominently recognizes patients at high risk of progression-free survival (PFS) events (P < 0.001), death (P < 0.001), grade 3/4 leukopenia (P = 0.010) and increased aspartate aminotransferase (P = 0.049). Interestingly, RBC-IMM score predicts the PFS more accurately than classical-IMM score (AUC = 0.766 and 0.596, P = 0.005). Clinico+RBC_index exhibits superior performance to clinico_index in terms of PFS with the addition of RBC-IMM score to clinical features. Furthermore, metabolomics analysis identifies phosphatidylcholine (PtdCho) notably involved in the interplay between RBC-mediated immuno-inflammation and CDKI efficacy, based on which clinico+PtdCho_index is developed to optimize PFS prediction of clinico_index. All these findings indicate that novel RBC-IMM related parameters have the advantage of identifying benefit and safety in CDKI-treated ABC patients over classical indicators, offering clinical implications of underlying mechanisms for erythroid lineage specific differential metabolites.
","dates":{"publication":"2025-04-15","submission":"2025-04-14"},"accession":"MTBLS10792","cross_references":{}}